Q-omics provides the consensus-scored DDX18P3 profile across patient tissues and cancer cell-line models. DDX18P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DDX18P3 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, DDX18P3 RNA expression shows 6,957 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight BLCA, THCA, and OV as cancer lineages where DDX18P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX18P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX18P3 survival associations across molecular data types. DDX18P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX18P3 RNA expression–survival associations across cancer types. High DDX18P3 expression shows unfavorable associations in CHOL, THCA and KICH, but favorable associations in BLCA, UCS and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for DDX18P3 RNA expression.
This table summarizes DDX18P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DDX18P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX18P3 shows lower tumor expression in THCA and KIRC and higher tumor expression in BLCA, BRCA, COAD and LUSC. The THCA box plot shows higher DDX18P3 RNA expression in normal versus tumor tissue (log2 FC = −0.137, t-test p < 0.001).
This table shows molecular features associated with DDX18P3 in patient tissues and cancer cell lines. In patient samples, DDX18P3 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
